Glaxo-Wellcome has narrowed its estimated $200 million media review down to a short list. A spokesman for incumbent Media Edge, New York, said, "No comment" when asked if it made the cut. Glaxo-Wellcome could not be reached for comment at press time. Rich O'Gorman of Blueprint Communications, Atlanta, is handling the review.
Copyright January 1999, Crain Communications Inc.